Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 4, 2006, Pages 485-518

  Yang, Feng ^a   Tong, Xianping ^b   McCarver, D Gail ^a   Hines, Ronald N ^a   Beard, Daniel A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

Age dependent; Children; Methadone; Pharmacokinetics; Physiologically based pharmacokinetic; Population study

Indexed keywords

CYTOCHROME P450 3A; METHADONE; OPIATE;

AGE; ARTICLE; CLINICAL PROTOCOL; COMPARTMENT MODEL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; HUMAN; MATHEMATICAL MODEL; MONTE CARLO METHOD; PEDIATRIC ANESTHESIA; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMULATION;

ADULT; AGE FACTORS; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHILD, PRESCHOOL; COMPUTER SIMULATION; HUMANS; HYDROGEN-ION CONCENTRATION; INFANT; INFANT, NEWBORN; MALE; METHADONE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PROTEIN BINDING; REGRESSION ANALYSIS; STEREOISOMERISM; TISSUE DISTRIBUTION;

EID: 33745621573     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9018-0     Document Type: Article

References (59)

1. R. A. Lugo, R. MacLaren, J. Cash, C. G. Pribble, and D. D. Vernon. Enterai methadone to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in the PICU. Pharmacotherapy 21:1566-1573 (2001).
2. J. D. Tobias. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit. Care. Med. 28:2122-2132 (2000).
3. J. D. Tobias, C. L. Schleien, and S. E. Haun. Methadone as treatment for iatrogenic narcotic dependency in pediatric intensive care unit patients. Crit. Care. Med. 18:1292-1293 (1990).
4. M. J. Garrido, R. Jiminez, E. Gomez, and R. Calvo. Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal. J. Pharm. Pharmacol. 48:281-284 (1996).
5. F. P. Abramson. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. Clin. Pharmacol. Ther. 32:652-658 (1982).
6. J. W. de Vos, P. J. Geerlings, W. van den Brink, J. G. Ufkes, and H. van Wilgenburg. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur. J. Clin. Pharmacol. 48:361-366 (1995).
7. E. D. Kharasch, C. Hoffer, D. Whittington, and P. Sheffels, Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76:250-269 (2004).
8. J. S. Wang, and C. L. DeVane. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31:742-747 (2003).
9. S. H. Wong, M. A. Wagner, J. M. Jentzen, C. Schur, J. Bjerke, S. B. Gock, and C. C. Chang. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? J. Forensic. Sci. 48:1406-1415 (2003).
10. K. Kristensen, T. Blemmer, H. R. Angelo, L. L. Christrup, N. E. Drenck, S. N. Rasmussen, and P. Sjogren. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther. Drug. Monit. 18:221-227 (1996).
11. D. W. Boulton, P. Arnaud, and C. L. DeVane. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin. Pharmacol. Ther. 70:48-57 (2001).
12. K. Wolff, A. W. Hay, D. Raistrick, and R. Calvert. Steady-state pharmacokinetics of methadone in opioid addicts. Eur. J. Clin. Pharmacol. 44:189-194 (1993).
13. E. Anggard, L. M. Gunne, J. Homstrand, R. E. McMahon, C. G. Sandberg, and H. R. Sullivan. Disposition of methadone in methadone maintenance. Clin. Pharmacol. Ther. 17:258-266 (1975).
14. C. E. Inturrisi, and K. Verebely. Disposition of methadone in man after a single oral dose. Clin. Pharmacol. Ther. 13:923-930 (1972).
15. A. E. Robinson, and F. M. Williams. The distribution of methadone in man. J. Pharm. Pharmacol. 23:353-358 (1971).
16. C. Iribarne, Y. Dreano, L. G. Bardou, J. F. Menez, and F. Berthou. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 117:13-23 (1997).
17. J. Lotsch, C. Skarke, I. Tegeder, and G. Geisslinger. Drug interactions with patient-controlled analgesia. Clin. Pharmacokinet. 41:31-57 (2002).
18. A. Ferrari, C. P. Coccia, A. Bertolini, and E. Sternieri. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol. Res. 50:551-559 (2004).
19. E. Bruera, and C. Sweeney. Methadone use in cancer patients with pain: a review. J. Palliat. Med. 5:127-138 (2002).
20. H. Rachel, A. Robert, W. Jason, H. Wayne, and F. Michael. Proceedings of the expert workshop on induction and stabilisation of patients onto methadone in Findings of an expert workshop, Adelaide, South Australia. ISBN 0642415080 (2000).
21. M. J. Garrido, and I. F. Troconiz. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J. Pharmacol. Toxicol. Methods 42:61-66 (1999).
22. R. Taj, E. Keenan, and J. J. O'Connor. A review of patients on methadone maintenance. Ir. Med. J. 88:218-219 (1995).
23. J. L. Gabrielsson, P. Johansson, U. Bondesson, and L. K. Paalzow. Analysis of methadone disposition in the pregnant rat by means of a physiological flow model. J. Pharmacokinet. Biopharm. 13:355-372 (1985).
24. C. B. Eap, T. Buclin, and P. Baumann. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41:1153-1193 (2002).
25. C. T. Walsh, R. R. Levine, and C. Squires. The gastrointestinal absorption of methadone in the rat. Drug Metab. Dispos. 3:525-529 (1975).
26. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50:387-412 (1998).
27. D. J. Foster, A. A. Somogyi, K. R. Dyer, J. M. White, and F. Bochner. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br. J. Clin. Pharmacol. 50:427-440 (2000).
28. D. J. Foster, A. A. Somogyi, and F. Bochner. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br. J. Clin. Pharmacol. 47:403-412 (1999).
29. D. G. Peck, and W. Beckett. Methadone maintenance: a review and critique. Br. J. Addict Alcohol Other Drugs 71:369-376 (1976).
30. J. C. Stevens, R. N. Hines, C. Gu, S. B. Koukouritaki, J. R. Manro, P. J. Tandler, and M. J. Zaya. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307:573-582 (2003).
31. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M. S. Boguski, and E. Schuetz. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:383-391 (2001).
32. M. I. Nilsson, U. Meresaar, and E. Anggard. Clinical pharmacokinetics of methadone. Acta. Anaesthesiol. Scand. Suppl. 74:66-69 (1982).
33. S. B. Charnick, R. Kawai, J. R. Nedelman, M. Lemaire, W. Niederberger, and H. Sato. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J. Pharmacokinet. Biopharm. 23:217-229 (1995).
34. M. Rowland, L. Balant, and C. Peck. Physiologically Based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci. 6:E6 (2004).
35. P. J. McNamara, and J. Alcorn. Protein binding predictions in infants. AAPS PharmSci. 4:E4 (2002).
36. D. G. McCarver, and R. N. Hines. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300:361-366 (2002).
37. R. N. Hines, and D. G. McCarver. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300:355-360 (2002).
38. S. Bjorkman. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol. 59:691-704 (2005).
39. G. Ginsberg, D. Hattis, A. Russ, and B. Sonawane. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health A 67:297-329 (2004).
40. P. S. Price, R. B. Conolly, C. F. Chaisson, E. A. Gross, J. S. Young, E. T. Mathis, and D. R. Tedder. Modeling interindividual variation in physiological factors used in PBPK models of humans Crit. Rev. Toxicol. 33:469-503 (2003).
41. ICRP 2002 Basic anatomical and physiological data for use in radiological protection: reference values ICRP. Publication 89 (ISSN: 0146 6453).
42. S. Haddad, C. Restieri, and K. Krishnan. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health A 64:453-464 (2001).
43. M. Boffito, K. Sciole, R. Raiteri, S. Bonora, P. G. Hoggard, D. J. Back, and G. Di Perri. Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens. Drug Metab. Dispos. 30:859-860 (2002).
44. W. L. Hayton. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2:E3 (2000).
45. S. A. Wrighton, W. R. Brian, M. A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Molowa, and M. Vandenbranden. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38:207-213 (1990).
46. C. Y. Sung, and E. L. Way. The metabolic fate of the optical isomers of methadone. J. Pharmacol. Exp. Ther. 109:244-254 (1953).
47. D. G. Levitt, and T. W. Schnider. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol. 5:4 (2005).
48. D. Farrar, B. Allen, K. Crump, and A. Shipp. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. Toxicol. Lett. 49:371-385 (1989).
49. N. Loimer, and R. Schmid. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depen. 30:241-246. (1992).
50. K. B. Sprenger, K. Huber, W. Kratz, and E. Henze. Nomograms for the prediction of patient's plasma volume in plasma exchange therapy from height, weight, and hematocrit. J. Clin. Apher. 3:185-190 (1987).
51. O. Linderkamp, H. T. Versmold, K. P. Riegel, and K. Betke. Estimation and prediction of blood volume in infants and children. Eur. J. Pediatr. 125:227-234 (1977).
52. D. S. Gray, and K. Fujioka. Use of relative weight and Body Mass Index for the determination of adiposity. J. Clin. Epidemiol. 44:545-550 (1991).
53. J. P. Clarys, A. D. Martin, and D. T. Drinkwater. Gross tissue weights in the human body by cadaver dissection. Hum. Biol. 56:459-473 (1984).
54. N. Ogiu, Y. Nakamura, I. Ijiri, K. Hiraiwa, and T. Ogiu. A statistical analysis of the internal organ weights of normal Japanese people. Health. Phys. 72:368-383 (1997).
55. B. J. Bailey, and G. L. Briars. Estimating the surface area of the human body. Stat. Med. 15:1325-1332 (1996).
56. T. Noda, T. Todani, Y. Watanabe, and S. Yamamoto. Liver volume in children measured by computed tomography. Pediatr. Radiol. 27:250-252 (1997).
57. Y. Watanabe, T. Todani, T. Noda, and S. Yamamoto. Standard splenic volume in children and young adults measured from CT images. Surg. Today 27:726-728 (1997).
58. B. L. Kasiske, and A. J. Umen. The influence of age, sex, race, and body habitus on kidney weight in humans. Arch Pathol. Lab. Med. 110:55-60 (1986).
59. A. S. Dekaban. Changes in brain weights during the span of human life: relation of brain weights to body heights and body weights. Ann. Neurol. 4:345-356 (1978).